29 results on '"Riechelmann, Rachel"'
Search Results
2. International comparison of the impact of COVID on adherence with supportive care focused Choosing Wisely recommendations (CWR).
3. Complementary and alternative medicine use among cancer patients at two cancer centers in Brazil.
4. Clinical outcomes of patients with gastric cancer according to pre and post-neoadjuvant chemotherapy PD-L1 immunohistochemistry (IHC) expression.
5. Prospective study of biomarkers in squamous cell carcinoma of the anal canal (SCCAC) and their influence on treatment outcomes: Five-year long-term results.
6. Characterization of the inflammatory infiltrate and association with expression of PD-1, PDL1 and PDL2 and survival in triple-negative mammary carcinoma.
7. Regorafenib in antiangiogenic-naive, chemotherapy-refractory advanced colorectal cancer: A phase IIb trial.
8. HER-2 overexpression in gastroesophageal junction (EGJ) adenocarcinoma as a predictor of prognosis in patients treated with perioperative chemotherapy.
9. Prospective study of biomarkers in squamous cell carcinoma of the anal canal (SCCAC) and their influence on treatment outcomes: Final results.
10. Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study.
11. The expression profile of biomarkers in squamous cell carcinoma of the anal canal and their influence on treatment outcomes: Preliminary results.
12. Evaluation of predictive biomarkers of response and prognosis in patients with high-grade extrapulmonary neuroendocrine carcinomas treated with platin-based chemotherapy.
13. High-grade extrapulmonary neuroendocrine carcinomas and small cell lung cancer: Different entities, same treatment.
14. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community.
15. The effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer: A meta-analysis of randomized trials.
16. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas.
17. A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment.
18. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.
19. Reply to R. Brierley et al
20. Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology
21. Should all patients (pts) with advanced biliary cancers receive first-line treatment with cisplatin and gemcitabine (GC)?
22. Poor Evidence to Standardize Adjuvant Treatment for Patients With Biliary Tract Cancer
23. Self-reported conflicts of interest (sfCOI) of authors and the interpretation of randomized phase III trials (RCT) and related editorials (REd) in cancer research.
24. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.
25. Progression-Free Survival in Neuroendocrine Tumors: Preferred End Point, But How Should It Be Defined?
26. Quality of Reporting Primary Outcomes in Phase II Cancer Trials
27. In Reply
28. Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology
29. Conflicts of Interest in Editorials in High-Impact Journals.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.